Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis

Inclusion Criteria: * Patients who have sclerosis located proximal to the elbow joint with diffused systemic scleroderma. * Patients who have not less than 20 points of TSS. * Patients with no appropriate therapeutic treatment. Exclusion Criteria: * Patients with severe hepatic disorder, severe renal disorder or severe heart disorder. * Patients with malignant tumors. * Patients who have the anamnesis of shock or hypersensitivity to this drug. * Patients who have the anamnesis of cerebral infarction or symptom of these diseases. * Patients who have been diagnosed as IgA deficiency in their past history. * Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant. * Patients who had any dose increase or new dosing of steroid within 12 weeks before consent. * Patients who were administered other investigational drug within 12 weeks before consent.